Navigation Links
Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM)

Study Suggests that Adding Singulair to Advair Offers no Additional

Improvement in Overall Asthma Control

RESEARCH TRIANGLE PARK, N.C. and TORONTO, May 18 /PRNewswire-FirstCall/ -- Patients with both asthma and allergic rhinitis, or seasonal allergies, experience significantly better lung function when treated with Advair Diskus(R) (fluticasone propionate and salmeterol inhalation powder) as compared with Singulair (montelukast sodium). The results of the 660-subject study were presented today at the International Conference of the American Thoracic Society meeting in Toronto.

The study also showed patients treated with Advair plus Singulair saw no measurable improvement compared to patients treated with Advair alone in their asthma symptoms or albuterol use. In another comparison patients using Advair plus the intranasal corticosteroid, fluticasone propionate nasal spray, saw significant improvement in daytime nasal symptoms compared to patients treated with Advair plus Singulair (p<0.001).

"These findings give us a greater understanding of how to treat patients with asthma and seasonal allergies, two diseases that often are seen in tandem," said Rohit Katial, MD, National Jewish Medical Research Center. "By using the right combination of treatments, physicians can help patients gain relief from the symptoms of both diseases."

The study included people age 15 and up who had both persistent asthma and seasonal allergies. Patients received one of four different treatments: Advair Diskus 100/50 twice daily, Singulair 10 mg once daily, Advair 100/50 twice daily with Singulair 10 mg once daily or Advair 100/50 twice daily with fluticasone propionate nasal spray 200 mcg once daily. Those who received Advair alone had significant improvements in their morning peak expiratory flow, a measure of asthma control, as compared with Singulair alone (p<0.001). Secondary endpoints, including symptom-free days and rescue-treatment-free days, were significantly increased in the Advair group compared with the Singulair group. The incidence of adverse events was similar among all groups.

Advair Diskus combines two medications in one device to help prevent and control asthma symptoms. Asthma causes inflammation (swelling in the airways) and airway constriction (the tightening of muscles that surround the airways), and Advair contains both an inhaled corticosteroid, fluticasone propionate, to reduce inflammation; and an inhaled long-acting bronchodilator, salmeterol, to help prevent and reduce airway constriction. Advair is for people who still have symptoms on another asthma controller, or whose disease severity clearly warrants treatment with two maintenance therapies.

Important Information about Advair

Advair won't replace fast-acting inhalers for sudden symptoms and should not be taken more than twice a day. Advair contains salmeterol. In patients with asthma, medicines like salmeterol may increase the chance of asthma- related death. So Advair is not for people whose asthma is well controlled on another controller medicine. People should speak to their doctor about the risks and benefits of treating their asthma with Advair. People taking Advair should see their doctor if their asthma does not improve. Thrush in the mouth and throat may occur. People should tell their doctor if they have a heart condition or high blood pressure. Some people may experience increased blood pressure, heart rate, or changes in heart rhythm. Advair Diskus is for patients 4 years and older. For patients 4 to 11 years old, Advair Diskus 100/50 is for those who have asthma symptoms while on an inhaled corticosteroid. Advair HFA is for patients 12 years and older.

For more information about Advair please visit

Important Information about Flonase

For best results, use Flonase daily. Your nasal symptoms may begin to improve in as few as 12 hours. Maximum relief may take several days. Results may vary. If side effects, they are generally mild and may include headache, nosebleed, or sore throat.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
2. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
3. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
4. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
7. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
8. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
9. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
10. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
11. Prism Glasses Expand the View for Patients with Hemianopia
Post Your Comments:
(Date:11/25/2015)... Research and Markets ( ) has ... Global Forecast to 2020" report to their offering. ... 37.21% of the total market share in 2014. The ... is projected to growth at the highest CAGR between ... to the fast growing water, industrial gas treatment, pharmaceutical, ...
(Date:11/25/2015)... , Frankreich, November 25, 2015 ... bekanntgegeben, dass sie eine Lizenz für das Patent über ... CNRS, UCBL und ENS-Lyon innehaben, an Enyo Pharma vergeben ... FUI AAP8 ins Leben gerufenen und von Edelris gemeinsam ... FXR als ein Behandlungsziel für HBV identifiziert, und es ...
(Date:11/25/2015)... November 25, 2015 ... addition of the  "Global Drug Device ... to their offering.  --> ... of the  "Global Drug Device Combination ... their offering.  --> Research ...
Breaking Medicine Technology:
(Date:11/24/2015)... Dallas, Texas (PRWEB) , ... November 24, 2015 , ... ... of all charitable donations are made in the last five weeks of the year ... #GivingTuesday was created in 2012 to connect the nation’s charities with those individuals who ...
(Date:11/24/2015)... , ... November 24, 2015 , ... DMG Productions announced ... Begley Jr., airing first quarter 2016 via Discovery Channel. Dates and show times TBA. ... Province, and is in the business of producing and supplying medical marijuana pursuant to ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Trustees, Massachusetts’ largest ... and parking fees at several of their most popular properties, including Crane Beach ... support of REI’s Black Friday #OptOutside Campaign. The Trustees encourage families and friends ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... ... With Thanksgiving right around the corner, holiday travel season is about to ... and vehicle. , According to the National Highway Traffic Safety Administration, 301 people were ... following safety tips from the NHTSA: , Inspect ...
Breaking Medicine News(10 mins):